Close Menu

This article has been updated with current information from Veracyte.

NEW YORK (GenomeWeb) – Investment bank Leerink has reinitiated coverage of Veracyte with an Outperform rating and a price target of $12 on the firm's stock.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.